Skip to content

Lifestyle monitoring and coaching using the mobile DIAMETER application in primary and secondary care (DIAMETER-1 study): protocol for a study on intervention usage and acceptability

Lifestyle monitoring and coaching using the mobile DIAMETER application in primary and secondary care (DIAMETER-1 study): protocol for a study on intervention usage and acceptability - Diameter-1

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON56033
Enrollment
90
Registered
2021-04-01
Start date
2022-01-13
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Diabetes Mellitus type 2

Interventions

Regular treatment in primary or secondary care or during COOL will be complemented with the Diameter: a mobile application which enables continuous monitoring of nutrition (via food diary), physical

Sponsors

Ziekenhuisgroep Twente
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Being diagnosed with type 2 diabetes; • Being treated in the outpatient clinic at ZGT or in primary care; • Being familiar with using a smartphone.

Exclusion criteria

Exclusion criteria: • Dependence on renal replacement therapy; • Severe general diseases or mental disorders making participation in the study impossible; • Insufficient mastery of the Dutch language; • Other CGM device than Freestyle Libre.

Design outcomes

Primary

MeasureTime frame
The main study parameters concern insight into the usability (phase 1), intervention usage (phase 2) and acceptability (phase 2) of the Diameter.

Secondary

MeasureTime frame
In phase 2, secondary objectives are to explore behavioural (e.g. physical activity), physiological (e.g. BMI), psychological (e.g. health-related quality of life) and clinical outcomes (e.g. glucose control, estimated HbA1c values).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)